Medicare Does Not Cover PRP Injections
Medicare does not pay for platelet-rich plasma (PRP) injections, as these are considered investigational and lack sufficient evidence of clinical efficacy for most indications.
Coverage Status and Rationale
Medicare, along with most major insurance carriers, classifies PRP as an experimental or investigational treatment and therefore excludes it from coverage. This policy stems from:
- Insufficient evidence of clinical benefit: The evidence base for PRP remains weak across most orthopedic and regenerative medicine applications 1
- Poor standardization: PRP preparations vary widely in content, purity, and biological properties, making it impossible to establish consistent treatment protocols 1
- Lack of cost-effectiveness: Economic analyses demonstrate that PRP is not cost-effective compared to standard treatments like total knee arthroplasty, primarily due to lack of established clinical efficacy rather than injection cost alone 2
Evidence Quality Concerns
The scientific community has identified critical limitations with PRP therapy 1:
- Clinical trials are generally underpowered with imprecise effect estimates
- Most studies fail to adequately define or quantify PRP biological properties
- Preparation methods lack standardization across providers and commercial devices
- The field shows "uncertain" utility for most clinical scenarios including tendon injuries, muscle injuries, bone healing, osteoarthritis, and sports injuries 1
Out-of-Pocket Costs
When patients pursue PRP despite lack of coverage, they face substantial financial burden:
- Mean reimbursement costs increased 266% from 2020-2024 (from $667 to $1,764 per injection) 3
- Total treatment costs (including clinic visits and procedures) can exceed $1,000-$3,700 depending on the protocol 4
- Significant access disparities exist: Higher-income patients from wealthier communities disproportionately utilize PRP, while uninsured and lower-income patients have minimal access 5
Exception: TRICARE Provisional Coverage
Notably, TRICARE (military health insurance) temporarily covered PRP for knee osteoarthritis and lateral epicondylitis from 2019-2024 without prior authorization 3. This program demonstrated:
- Dramatic increases in utilization (from 657 injections in 2020 to 4,140 in 2024)
- Potential for exploitation (one clinic received over $7 million in reimbursement)
- Most injections (92%) met or potentially met coverage criteria
However, this provisional program has ended, and the experience illustrates concerns about covering treatments with weak evidence bases.
Clinical Implications
If patients inquire about PRP, counsel them that:
- They will be responsible for 100% of costs
- Evidence supporting PRP efficacy remains limited and inconsistent
- Standard evidence-based treatments (physical therapy, corticosteroid injections, hyaluronic acid for knee OA, or surgical interventions when appropriate) are covered by Medicare and have stronger supporting evidence
The lack of Medicare coverage reflects the current state of scientific evidence rather than arbitrary policy decisions.